 | • レポートコード：MRC2303K111 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の吸入一酸化窒素市場規模が、予測期間中、CAGR 4.6％で増大すると予測されています。本レポートでは、吸入一酸化窒素の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別（ガス、デリバリーシステム）分析、用途別（新生児呼吸器治療、気管支喘息・COPD、急性呼吸困難症候群、マラリア治療、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Air Liquide Healthcare、Mallinckrodt、Matheson Tri-Gas Inc.、Merck KGaA、Novoteris、Nu-Med Plus、Perma Pure LLC、Praxair Technology Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の吸入一酸化窒素市場規模：製品種類別 - 吸入一酸化窒素ガスの市場規模 - 吸入一酸化窒素デリバリーシステムの市場規模 ・世界の吸入一酸化窒素市場規模：用途別 - 新生児呼吸器治療における市場規模 - 気管支喘息・COPDにおける市場規模 - 急性呼吸困難症候群における市場規模 - マラリア治療における市場規模 - その他用途における市場規模 ・世界の吸入一酸化窒素市場規模：地域別 - 北米の吸入一酸化窒素市場規模 アメリカの吸入一酸化窒素市場規模 カナダの吸入一酸化窒素市場規模 メキシコの吸入一酸化窒素市場規模 … - ヨーロッパの吸入一酸化窒素市場規模 ドイツの吸入一酸化窒素市場規模 イギリスの吸入一酸化窒素市場規模 フランスの吸入一酸化窒素市場規模 … - アジア太平洋の吸入一酸化窒素市場規模 中国の吸入一酸化窒素市場規模 日本の吸入一酸化窒素市場規模 インドの吸入一酸化窒素市場規模 … - 南米/中東の吸入一酸化窒素市場規模 南アフリカの吸入一酸化窒素市場規模 ブラジルの吸入一酸化窒素市場規模 アルゼンチンの吸入一酸化窒素市場規模 … ・競争状況 ・市場機会・将来動向 |
The inhaled nitric oxide market is anticipated to register a CAGR of nearly 4.6%, during the forecast period.
Key Highlights
- Certain factors that are driving the market growth include rising prevalence of respiratory and other associated diseases and ongoing research and development activities.
- Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. Since the acknowledgment of nitric oxide (NO) as a key endothelial-derived vasodilator molecule in the last century, the field of NO research has expanded to encompass several areas of biomedical research. At present, it is well established that NO is an important signaling molecule throughout the body.
- Recent data suggest that inhaled NO can be applied in a wide variety of diseases. For instance, studies indicate that inhaled NO is a safe and effective agent to determine the vasodilatory capacity of the pulmonary vascular bed.
- Current evidence also shows that iNO improves oxygenation and decreases the combined outcome of death or necessity for extracorporeal membrane oxygenation in infants of more than 35 weeks’ gestational age at birth. Owing to all the aforementioned factors, the market is expected to observe steady growth over the forecast period.
Inhaled Nitric Oxide Market Trends
Asthma and COPD Shows Lucrative Growth in the Inhaled Nitric Oxide Market
· The American Academy of Allergy Asthma and Immunology (AAAI) states that, in 2016, approximately 8.3% of children in the United States was found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively.
· Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among subdemographic groups studied, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.
· According to the CDC, during 2013–2017, an estimated 2.4 million (2.2%) US working adults aged more than 18 years who never smoked had COPD. The highest COPD prevalences among persons who never smoked were in the information (3.3%) and mining (3.1%) industries and office and administrative support occupation workers (3.3%). Women had higher COPD prevalences than did men.
· Moreover, as per the 2019 report published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide.
North America Dominates the Inhaled Nitric Oxide Market
· According to a 2020 article by Matthew Diamond, estimates of the incidence of ARDS in the United States range from 64.2 to 78.9 cases/100,000 person-years. 25% of ARDS cases are initially classified as mild and 75% as moderate or severe. However, a third of the mild cases go on to progress to moderate or severe disease.
· In addition, asthma prevalence was highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey.
· The source also states that participants in the educational services industry reported the second-highest rate of asthma at 8.2%. Hence, the growing prevalence of respiratory diseases is expected to contribute to the significant market share of North America over the forecast period.
Inhaled Nitric Oxide Market Competitor Analysis
The market is competitive and consists of a number of players. In February 2020, Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Companies like Air Liquide Healthcare, Mallinckrodt, Matheson Tri-Gas Inc., Merck KGaA, Novoteris, Nu-Med Plus, Perma Pure LLC, Praxair Technology Inc., hold the substantial market share in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Respiratory and Other Associated Diseases
4.2.2 Ongoing Research and Development Activities
4.3 Market Restraints
4.3.1 Strict Apllication Norms across Various Regions
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Gas
5.1.2 Delivery Systems
5.2 By Application
5.2.1 Neonatal Respiratory Treatment
5.2.2 Asthma and COPD
5.2.3 Acute Respiratory Distress Syndrome
5.2.4 Malaria Treatment
5.2.5 Tuberculosis Treatment
5.2.6 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Air Liquide Healthcare
6.1.2 Mallinckrodt
6.1.3 Matheson Tri-Gas Inc.
6.1.4 Merck KGaA
6.1.5 Novoteris
6.1.6 Nu-Med Plus
6.1.7 Perma Pure LLC
6.1.8 Praxair Technology Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS